BACKGROUND: Electroacupuncture (EA) has therapeutic effects on @entity9 induced by @entity128 ; however, the underlying mechanisms remain unclear. In this study, we examined whether EA treatment relieves @entity158 @entity56 via the down-regulation of spinal P2X7 receptor-positive (P2X7R) microglia-mediated overexpression of @entity3426 and/or @entity7270 . METHODS: Male @entity35 underwent @entity8638 ( @entity8638 ) or @entity22657 ( @entity22657 ) intrathecal injection. Von Frey and Hargreaves tests were performed to evaluate the effect of EA on @entity158 @entity56 . The spinal P2X7R, @entity3426 , and @entity7270 expression levels were determined by real-time polymerase chain reaction, Western blot analysis, immunofluorescence staining, and enzyme-linked immunosorbent assay. The selective P2X7R antagonist @entity33900 was used to examine the P2X7R microglia-dependent release of @entity3426 and @entity7270 . Primary cultures were subsequently used to assess the P2X7R microglia-induced @entity3426 and @entity7270 release. RESULTS: EA treatment significantly improved the @entity158 thresholds and inhibited spinal P2X7R microglia activation induced by @entity8638 or @entity22657 administration, which was accompanied by the suppression of spinal @entity3426 and @entity7270 overexpression. Moreover, @entity33900 also improved @entity158 thresholds and suppressed overexpression of @entity3426 in the @entity8638 - and @entity22657 -injected @entity35 . The analysis of cultured microglia further demonstrated that @entity33900 markedly decreased @entity22657 -induced @entity3426 release. CONCLUSIONS: EA treatment relieves @entity128 -induced @entity1931 and thermal @entity1931 via the inhibition of P2X7R microglia-mediated @entity3426 overexpression.

Electroacupuncture Relieves Nerve XXXX via the Inhibition of Spinal P2X7 Receptor-Positive Microglia.

@entity1931 :: ('MESH:D006930', 'Disease') :: ['hyperalgesia', 'tactile allodynia'] @entity128 :: ('MESH:D020209', 'Disease') :: ['nerve injury'] @entity7270 :: ('29197(Tax:10116)', 'Gene') :: ['IL-18'] @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity'] @entity3426 :: ('24494(Tax:10116)', 'Gene') :: ['IL-1b', 'interleukin (IL)-1b'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity33900 :: ('MESH:C523668', 'Chemical') :: ['A-438079'] @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats'] @entity22657 :: ('MESH:C033901', 'Chemical') :: ['BzATP', "3'-O-(4-benzoylbenzoyl) adenosine 5'-triphosphate"] @entity8638 :: ('MESH:D020208', 'Disease') :: ['chronic constriction injury', 'CCI'] @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']
@entity56 :: (MESH:D004342,Disease) :: ['Injury-Induced Pain Hypersensitivity']
